학술논문
PHASE 2 RANDOMIZED STUDY (ORION-1) OF A NOVEL, BIODEGRADABLE DEXAMETHASONE IMPLANT (AR-1105) FOR THE TREATMENT OF MACULAR EDEMA DUE TO CENTRAL OR BRANCH RETINAL VEIN OCCLUSION
Document Type
Article
Author
Source
Retina; January 2023, Vol. 43 Issue: 1 p25-33, 9p
Subject
Language
ISSN
0275004X; 15392864
Abstract
Supplemental Digital Content is Available in the Text.AR-1105 is a novel biodegradable, sustained-release intravitreal dexamethasone implant formulated to provide 6-month durability. Two formulations of AR-1105 with different release profiles were well tolerated and demonstrated clinically meaningful and sustained improvements in vision and reduction in retinal thickening despite longstanding edema due to branch or central retinal vein occlusion.